Transition-Metal Complexes for Cancer Therapy and Light-Emitting Devices
This community develops coordination compounds of platinum, ruthenium, iridium, and other metals for two distinct purposes: treating cancer and creating organic light-emitting diodes.
The work centers on synthesizing and characterizing metal complexes, often using Schiff base ligands, to evaluate their anticancer activity against ovarian, breast, and lung cancer cells. A significant portion of the research addresses cisplatin resistance and platinum-based chemotherapy, exploring alternatives like ruthenium and copper complexes. Simultaneously, the community designs cyclometalated iridium and platinum emitters for organic light-emitting diodes, focusing on photodynamic therapy applications and molecular docking simulations to predict biological interactions. Crystal structure analysis is a recurring method for validating the synthesis of these compounds.
The community represents a substantial share of research in rhenium, ruthenium, and platinum, accounting for 27.6%, 21.7%, and 21.7% of all tracked papers for those elements, respectively. It contains 36,331 papers, primarily published in Inorganic Chemistry, Dalton Transactions, and Inorganica Chimica Acta.
Recent work includes iridium complexes for photodynamic therapy, ruthenium-based photocages for drug activation, and platinum emitters for deep-blue OLEDs, alongside clinical studies on platinum-resistant ovarian cancer.
Papers behind this description
- Molecular docking as a tool for the discovery of molecular targets of nutraceuticals in diseases management β Scientific Reports, 2023 β doi:10.1038/s41598-023-40160-2
- Overall Survival with Pembrolizumab in Early-Stage Triple-Negative Breast Cancer β New England Journal of Medicine, 2024 β doi:10.1056/nejmoa2409932
- Ovarian Cancer β JAMA, 2025 β doi:10.1001/jama.2025.9495
- Mirvetuximab Soravtansine in FRΞ±-Positive, Platinum-Resistant Ovarian Cancer β New England Journal of Medicine, 2023 β doi:10.1056/nejmoa2309169
- Recent Strategies to Develop Innovative Photosensitizers for Enhanced Photodynamic Therapy β Chemical Reviews, 2021 β doi:10.1021/acs.chemrev.1c00381
- Durvalumab Plus Carboplatin/Paclitaxel Followed by Maintenance Durvalumab With or Without Olaparib as First-Line Treatment for Advanced Endometrial Cancer: The Phase III DUO-E Trial β Journal of Clinical Oncology, 2024 β doi:10.1200/jco.23.02132
- Clinical and translational advances in ovarian cancer therapy β Nature Cancer, 2023 β doi:10.1038/s43018-023-00617-9
- Platinum-based drugs for cancer therapy and anti-tumor strategies β Theranostics, 2022 β doi:10.7150/thno.69424
- Targeting epigenetic regulators as a promising avenue to overcome cancer therapy resistance β Signal Transduction and Targeted Therapy, 2025 β doi:10.1038/s41392-025-02266-z
- Mitochondria-targeted BODIPY dyes for small molecule recognition, bio-imaging and photodynamic therapy β Chemical Society Reviews, 2024 β doi:10.1039/d3cs00456b
- Reprogramming of cancer metabolism via photoresponsive nano-PROTAC enhances pyroptosis-mediated immunotherapy β Signal Transduction and Targeted Therapy, 2025 β doi:10.1038/s41392-025-02405-6
- Multifunctional Chitosan/Mn(II) Complexes: Preparation, Catalytic Activity in Imine Synthesis and Aldol Reaction, and Effect on Milk Fermentation/Post-Acidification β Molecules, 2025 β doi:10.3390/molecules30234522
- Pembrolizumab plus weekly paclitaxel in platinum-resistant recurrent ovarian cancer (ENGOT-ov65/KEYNOTE-B96): a multicentre, randomised, double-blind, phase 3 study β The Lancet, 2026 β doi:10.1016/s0140-6736(26)00602-100602-1)
- Colorectal Cancer at the Crossroads: The Good, the Bad, and the Future of Platinum-Based Drugs β Chemical Reviews, 2025 β doi:10.1021/acs.chemrev.5c00041
- Engineering iridium(III) complexes for enhancing electron transfer-based photodynamic therapy β Coordination Chemistry Reviews, 2026 β doi:10.1016/j.ccr.2026.217877
- Advances in copper complexes in cancer treatment β Drug Discovery Today, 2025 β doi:10.1016/j.drudis.2025.104522